Orthopedics This Week

When Zimmer Biomet announced that it intended to buy LDR for $1 billion, investors immediately turned their attention to NuVasive, Globus and other fast growing, independent spine companies. Is Zimmer’s bid a sign that spine may start consolidating? Wall Street thinks so. But Wall Street would. What’s the real story?